Guangdong Baoli Pharmaceutical's 4 Billion-Dose Formulation Project Commences Construction, Boosting Logistics and Supply Chain

Deep News
01/22

The Guangdong Baoli Pharmaceutical annual 4 billion tablet (capsule) formulation project has officially commenced construction in Shatang Town, Kaiping City, Jiangmen. Located in Shatang Town, Kaiping City, Jiangmen, Guangdong Province, the project is being constructed by CCCC Fourth Harbor Engineering Bureau Co., Ltd. and involves the planned development of three major sections: production support facilities, administrative support buildings, and outdoor ancillary infrastructure. These will encompass core functional areas such as a combined workshop, a comprehensive formulation workshop, a penicillin workshop, and a hazardous materials warehouse.

Beyond its production scale, the project's "engine" effect is also reflected in its high-standard factory buildings and comprehensive supporting facilities, which are expected to attract more upstream and downstream supporting enterprises, R&D institutions, and high-end talent to gather in Kaiping. It is anticipated that this will drive the formation of a complete industrial chain, ranging from active pharmaceutical ingredient supply and excipient production to packaging materials, R&D services, and logistics distribution, thereby upgrading the regional biopharmaceutical industry ecosystem towards greater vitality and resilience.

Liu Chao, Deputy Head of the Project Engineering Department at CCCC Fourth Harbor Engineering Bureau, stated that the project team will strictly adhere to the construction requirements of "high standards, high quality, and high efficiency." A seasoned management team and a pool of technical experts will be assembled to meticulously organize scientific planning and strengthen quality and safety control throughout the entire process, striving to complete the project as soon as possible.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10